Twist Bioscience Q3 2025 Earnings Call Scheduled for August 4

Twist Bioscience to Report Fiscal 2025 Third Quarter Financial Results on Monday, August 4, 2025

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Tags

conferences earnings

07/14/2025 - 08:00 AM

Company to host conference call at 8:00 AM ET

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it will issue its financial results for the fiscal 2025 third quarter ended June 30, 2025, before the opening of the market on August 4, 2025. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company鈥檚 business. The press release with the financial results will be accessible from the company鈥檚 website prior to the conference call through the Investor Relations section under the 鈥淐ompany鈥� tab at .

The conference call will be webcast live through the Investor Relations section under the 鈥淐ompany鈥� tab at . Those parties interested in participating via telephone must register on the Company鈥檚 Investor Relations website or by clicking . Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast replay will be available for two weeks.

About Twist Bioscience Corporation

At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture and industrial chemicals, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts.

Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. For more information about our products and services, please visit .